You have accessJournal of UrologyBladder Cancer: Detection and Screening I1 Apr 2015PD23-04 THE POTENTIAL UTILITY OF CHEMOKINE CXCL1 (GROα) AS A NOVEL DIAGNOSTIC AND PROGNOSTIC MARKER FOR BLADDER CANCER Takashi Kobayashi, Yoshiyuki Matsui, Takuro Sunada, Takahiro Inoue, Tomomi Kamba, and Osamu Ogawa Takashi KobayashiTakashi Kobayashi More articles by this author , Yoshiyuki MatsuiYoshiyuki Matsui More articles by this author , Takuro SunadaTakuro Sunada More articles by this author , Takahiro InoueTakahiro Inoue More articles by this author , Tomomi KambaTomomi Kamba More articles by this author , and Osamu OgawaOsamu Ogawa More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1420AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Cystoscopy is a standard diagnostic and follow-up tool of bladder cancer (BCa), but it is invasive and painful for patients. Therefore, novel urinary molecular markers which are non-invasive but have a high sensitivity even for low-grade tumors have been explored. Here, we show an improved accuracy at measuring urinary CXCL1 (uCXCL1) by a newly developed ELISA system and at predicting the presence and prognosis of bladder cancer. METHODS We produced a monoclonal antibody against human CXCL1 by immunization of BALB/c mice with CXCL1 fusion protein and developed new ELISA system using that antibody. As a first part, CXCL1 levels were determined in the set of urine samples from total of 68 BCa patients (22 of low grade pTa, 21 of high grade pTa, 21 of pT1-pT3 and 4 of pTis), 43 other urological disease control samples and 20 healthy control samples. The sensitivity and specificity of uCXCL1 concentration normalized by urine creatinine (CXCL1/Cre) were compared with those of commercially available markers (NMP22 and BTATRAK). As a second part, urine CXCL1/Cre in 175 patients with BCa was measured and the predictive ability for intravesical recurrence after transurethral resection (TUR) was examined. RESULTS In the first part, the values of uCXCL1 increased according to stage of BCa. uCXCL1 was superior to NMP22 and BTA in sensitivity (81%, 37% and 79% for CXCL1, NMP22 and BTA, respectively) and had a high specificity (80%, 95% and 60%, respectively). AUC values of ROC curves were 0.875, 0.656 and 0.814 for CXCL1, NMP22 and BTA, respectively. Even for distinguishing BCa with other urological disease subjects, CXCL1 gave higher AUC values (0.633) than the conventional markers (0.514 and 0.621 for NMP22 and BTA, respectively). In the latter part, patients who showed higher CXCL1/Cre were significantly more likely to develop intravesical recurrence after TUR. CXCL1/Cre was also able to separate BCa patients with EORTC intermediate-risk into high and low probabilities of post-TUR recurrence equivalent to EORTC high- and low-risk group, respectively. In multivariate analysis, CXCL1/Cre was an independent predictor for post-TUR intravesical recurrence (p = 0.009). CONCLUSIONS We showed the usefulness of urinary CXCL1 as a novel urinary molecular marker for BCa detection and prediction of NMIBC recurrence using a new ELISA system, which would be able to reduce the frequency of cystoscopy and compensate for low sensitivity of urinary cytology in BCa patients. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e482 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Takashi Kobayashi More articles by this author Yoshiyuki Matsui More articles by this author Takuro Sunada More articles by this author Takahiro Inoue More articles by this author Tomomi Kamba More articles by this author Osamu Ogawa More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...